Avanos Medical, Inc. AVNS NYSE

Avanos Medical, Inc. (AVNS) has a negative trailing P/E of -9.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 24.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -10.55%, forward earnings yield 4.06%. PEG 0.99 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

• VALUE (35/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -9.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -10.55%).
• Forward P/E 24.6 — analysts expect a return to profitability with estimated EPS of $1.00 for FY2026.
• PEG Ratio 0.99 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
• Trailing Earnings Yield -10.55% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 4.06% as earnings recover.
• Analyst consensus target $23.00 (-6.6% downside) — slight downside risk — the market may be ahead of analyst expectations.

Overall SharesGrow Score: 32/100 with 0/7 criteria passed.